MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Ophthalmologist

  • September 12, 2026
Alcon Brings Next-Generation Cataract Technologies to ESCRS
  • September 12, 2026
  • 3 min
  1. Alcon will showcase its surgical technologies at the 44th ESCRS Congress in London from September 11–15, 2026.
  2. The Clareon PanOptix Pro, a new trifocal IOL, aims to enhance visual performance and light utilization compared to its predecessor.
  3. Alcon will introduce the Clareon TruPlus enhanced monofocal IOL, designed to improve intermediate vision while maintaining distance vision.
  4. The UNITY Cataract System will feature technologies aimed at improving phaco efficiency and surgical control during cataract procedures.
  5. Alcon plans to launch its Science Expert Network in Europe and host sessions on IOL innovation and cataract surgery efficiency.
...more

MDSpire News

  • September 11, 2026
Can external counterpulsation help early Alzheimer disease?
  • Kathryn Wighton
  • September 11, 2026
  • 5 min

Objective: To evaluate the efficacy of full-pressure external counterpulsation (ECP) compared to low-pressure treatment in improving cognition and activities of

...more

MDSpire News

  • September 11, 2026
Nasal obstruction may worsen OSA indicators
  • Andrea Surnit
  • September 11, 2026
  • 4 min

Objective: To examine the effects of nasal obstruction and mouth taping on obstructive sleep apnea (OSA) indicators. Approach: Study Search: Investigators searc

...more

MDSpire News

  • September 11, 2026
Robotic knee surgery put to the test
  • Kathryn Wighton
  • September 11, 2026
  • 3 min

Objective: To compare the effectiveness of robotic-arm–assisted total knee replacement with conventional total knee replacement in patients with advanced knee o

...more
2 min

MDSpire News

  • September 11, 2026
Adenotonsillectomy linked to more RTI visits
  • Kathryn Wighton
  • September 11, 2026
  • 5 min

Objective: To assess the association between adenotonsillectomy and hospital visits for respiratory tract infections (RTIs) in pediatric patients. Approach: Stu

...more

MDSpire News

  • September 11, 2026
Pediatric abscess incidence may be higher postpandemic
  • Andrea Surnit
  • September 11, 2026
  • 4 min

Objective: To evaluate the incidence of pediatric head and neck abscesses across different periods: prepandemic, during COVID-19 lockdown, and postpandemic. App

...more

MDSpire News

  • September 11, 2026
What it takes to integrate clinical AI
  • Matthew Solan
  • September 11, 2026
  • 7 min
  1. Organizations face challenges integrating AI into clinical practice without compromising clinical judgment and quality of care.
  2. AI adoption in healthcare is uneven, with varying applications and potential risks influencing the pace of integration.
  3. Successful AI implementation requires rethinking existing workflows rather than simply adding AI to current processes.
  4. Reliance on AI may erode skills in healthcare professionals, necessitating a balance between using AI and maintaining proficiency.
  5. Future physicians will need competence, communication, and character to effectively utilize AI and ensure patient care.
...more

MDSpire News

  • September 11, 2026
Does childhood BMI relate to later reproduction?
  • Kathryn Wighton
  • September 11, 2026
  • 4 min
  1. Women with overweight or obesity BMI trajectories during childhood had lower hazards of giving birth starting at ages 25 to 29 years.
  2. The study analyzed data from women born in Copenhagen, Denmark, between 1950 and 1989, following them for reproductive outcomes through December 2022.
  3. Among 60,864 women in the childbirth analysis, 78% (47,669) gave birth, with associations between childhood BMI and childbirth becoming more pronounced at older ages.
  4. Childhood BMI trajectories were not associated with primary infertility, although women with an obesity trajectory had a lower hazard of primary infertility.
  5. The study noted that lower educational attainment may lead to underestimation of infertility among women with lower socioeconomic positions.
...more

Inside Dentistry

  • September 11, 2026
SafeLink Consulting Launches SafeLink360 Compliance Management Platform
  • September 11, 2026
  • 2 min
  1. SafeLink Consulting Inc. launched SafeLink360, a compliance management platform for organizations under regulatory requirements.
  2. SafeLink360 offers a centralized system for managing compliance activities from assessment through resolution.
  3. The platform supports document management, task tracking, structured assessments, training, and regulatory reporting.
  4. SafeLink360 is designed for various sectors, including dental practices, laboratories, medical providers, and general industry.
  5. The platform integrates compliance expertise with technology, tailored to meet the unique needs of each organization.
...more

Inside Dentistry

  • September 11, 2026
Pima Medical Institute Launches Dental Hygiene Program in Phoenix
  • September 11, 2026
  • 3 min

Objective: To establish a Dental Hygiene program at the Phoenix campus to address workforce shortages in Arizona. Approach: Program Details: The 18-month progra

...more

The Pathologist

  • September 11, 2026
Urine Bladder Cancer Test Could Triage Cystoscopy
  • September 11, 2026
  • 2 min

Objective: To evaluate the effectiveness of the GALEAS Bladder assay in triaging patients with hematuria for urgent cystoscopy. Approach: Study Design: A prospe

...more

The Ophthalmologist

  • September 11, 2026
STAAR Surgical Showcases EVO ICL Innovation and Clinical Insights
  • September 11, 2026
  • 3 min
  1. STAAR Surgical will showcase its EVO ICL technology at the 44th ESCRS Congress in London from September 11–15, 2026.
  2. Over four million EVO ICLs have been sold globally, with CE Mark approval received in Europe in 2011.
  3. EVO ICL indications have expanded to include patients up to 60 years and as a supplemental lens after cataract surgery.
  4. EVO Insights LIVE will feature small-group sessions addressing practical topics in EVO ICL management for surgeons.
  5. The EVO ICL is made from proprietary Collamer® material, offering optical quality and compatibility without corneal tissue removal.
...more

The Ophthalmologist

  • September 11, 2026
ZEISS Unveils Cataract-Only EVA NEXUS
  • September 11, 2026
  • 3 min

Objective: To introduce a dedicated cataract-only configuration of the DORC EVA NEXUS ophthalmic surgical system. Approach: Product Launch: The cataract-only co

...more
2 min

The Medicine Maker

  • September 11, 2026
Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?
  • September 11, 2026
  • 2 min

Objective: To explore how the cell and gene therapy sector can rethink value, access, and affordability as therapies transition from clinical trials to routine

...more
1 min

Journal Of Medical Internet Research

  • September 11, 2026
Healthcare Professionals' Perspectives on Integrating Artificial Intelligence in Mental Health Services: A Scoping Review
  • Carly Hudson
  • Thuy Linh Phan
  • Marcus Randall
  • September 11, 2026

Objective: To examine healthcare professionals' perspectives on the integration of artificial intelligence (AI) in mental health services. Approach: Review Meth

...more

Journal Of Medical Internet Research

  • September 11, 2026
Efficacy of Wearable Digital Therapeutics in Enhancing Sleep Quality for Individuals with Insomnia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  • Wenhui Zhu
  • Mingming Chen
  • Yixuan Guo
  • Bin Zhang
  • Chunliu Luo
  • September 11, 2026
  1. Insomnia affects 10% to 20% of adults, with higher prevalence in women and older populations.
  2. Insomnia is linked to mental disorders, reduced quality of life, and significant economic burdens exceeding $100 billion annually in the U.S.
  3. Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment, but access is limited due to therapist shortages and high costs.
  4. Benzodiazepine receptor agonists provide temporary relief for insomnia but carry risks such as dependence and cognitive impairment.
  5. Health care systems are prioritizing the identification of safe, effective, and scalable insomnia interventions due to its public health impact.
...more

World Journal Of Urology

  • September 11, 2026
A Six-Factor Stratification Approach for Enfortumab Vedotin Treatment in Previously Treated Patients with Advanced Urothelial Carcinoma
  • Yuto Matsushita
  • Satoru Taguchi
  • Taku Naiki
  • Gaku Ishikawa
  • Yu Nakamura
  • Jimpei Miyakawa
  • Takashi Nagai
  • Tomoyuki Kaneko
  • Hiroki Kubota
  • Hayato Hoshina
  • Jun Kamei
  • Aya Niimi
  • Yuta Yamada
  • Daisuke Obinata
  • Shigenori Kakutani
  • Masashi Shiozaki
  • Kento Ozawa
  • Michio Noda
  • Daichi Hirata
  • Yuichi Kitagawa
  • Yukihiro Yoshimi
  • Nozomi Sugiyama
  • Nobuhiko Shimizu
  • Yohei Tsubouchi
  • Keigo Sato
  • Kosuke Uchida
  • Shinya Watanabe
  • Jun Takahashi
  • Toshiharu Morikawa
  • Yoichi Mori
  • Takashi Murata
  • Taro Murata
  • Taketo Kawai
  • Takehiro Tanaka
  • Yukari Uemura
  • Tappei Takada
  • Sayuri Takahashi
  • Toshiki Ito
  • Masao Nagata
  • Hideyo Miyazaki
  • Satoshi Kurokawa
  • Yukio Yamada
  • Ryo Sato
  • Atsushi Otsuka
  • Yusuke Sato
  • Hiroaki Nishimatsu
  • Yukihiro Umemoto
  • Hiroshi Furuse
  • Yoshiyuki Akiyama
  • Yutaka Enomoto
  • Satoru Takahashi
  • Tetsuya Fujimura
  • Tohru Nakagawa
  • Hiroshi Fukuhara
  • Takahiro Yasui
  • Haruki Kume
  • Teruo Inamoto
  • September 11, 2026
  1. The EV-301 trial demonstrated that enfortumab vedotin (EV) monotherapy offers oncological benefits over standard chemotherapy for advanced urothelial carcinoma.
  2. A multicenter retrospective study analyzed 482 patients with advanced urothelial carcinoma treated with EV monotherapy to identify prognostic factors.
  3. The study identified six common poor prognostic factors for progression-free survival and overall survival: poor ECOG performance status, aberrant histology, and others.
  4. Median progression-free survival was 7.6 months, while median overall survival was 14.6 months among the 387 patients evaluated in the study.
  5. The study's findings contribute to the understanding of prognostic risk factors, aiding in the stratification of patients receiving EV treatment.
...more

Jama Network Open

  • September 11, 2026
Addressing Maternal Injury from Violence and Children's Exposure to Aggression—Advocating for Trauma-Informed and Systemic Approaches
  • Gunjan Tiyyagura
  • M. Katherine Henry
  • Kimberly A. Randell
  • September 11, 2026

Objective: To highlight the association between maternal violent injury and subsequent child physical and sexual injury, while advocating for trauma-informed re

...more